We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current SMMT market cap is 13.27B. The company's latest EPS is USD -0.8339 and P/E is -21.43.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 822k | 179k | 213k | 159k | -264k |
Operating Income | -19.94M | -36.21M | -42.39M | -59.62M | -58.38M |
Net Income | -21.27M | -36.57M | -43.47M | -60.39M | -56.25M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 23.62M | 20.17M | 22.78M | 15.12M | 1M |
Operating Income | -27.47M | -53.19M | -86.19M | -72.09M | -609.65M |
Net Income | -29.13M | -52.7M | -88.6M | -78.78M | -614.93M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 218.48M | 202.95M | 176.78M | 341.86M | 502.85M |
Total Liabilities | 119.1M | 125.26M | 132.57M | 146.78M | 64.93M |
Total Equity | 99.38M | 77.69M | 44.21M | 195.08M | 437.92M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 96.25M | 102.5M | 113.37M | 664.17M | 202.95M |
Total Liabilities | 17.39M | 23.05M | 30.09M | 537.51M | 125.26M |
Total Equity | 78.86M | 79.45M | 83.28M | 126.65M | 77.69M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -57.3M | -76.76M | -30.13M | -63.14M | -93.43M |
Investing | -648.34M | -587.77M | 19.87M | -180.21M | -288.82M |
Financing | 80.26M | 86.51M | 485k | 200.7M | 404.84M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -20.76M | -48.11M | -72.59M | -41.58M | -76.76M |
Investing | -341k | -421k | -306k | -624k | -587.77M |
Financing | 49.51M | 50.55M | 77.92M | 620.24M | 86.51M |
Market Cap | 13.27B |
Price to Earnings Ratio | -21.43 |
Price to Sales Ratio | 12.76k |
Price to Cash Ratio | 184.42 |
Price to Book Ratio | 169.62 |
Dividend Yield | - |
Shares Outstanding | 737.45M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 1.04 (5.49%) |
Company Name | Summit Therapeutics Inc |
Address |
850 new burton road suite 201 wilmington, delaware 19904 |
Website | https://www.smmttx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions